Loading
Life sciences · Journal article
Cancer Research · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
While chimeric antigen receptor (CAR)-engineered T and NK cell therapies have revolutionized hematological malignancy treatment, translating this success to solid tumors remains a persistent challenge. Here, we demonstrated a stromal-associated metabolic mechanism in which cancer-associated fibroblasts (CAFs) and macrophage-associated populations in gastrointestinal cancers contribute to CAR loss through CYP27A1-derived 27-hydroxycholesterol (27HC). 27HC triggered membrane cholesterol depletion, destabilizing lipid rafts and promoting the release of full-length CAR in ARF6+CD81+ microvesicle-enriched fractions. NK92 cells chronically exposed to sublethal 27HC adapted to this stress via an AKT-FOXO1-insulin receptor (INSR) signaling cascade that restores cholesterol biosynthesis. Capitalizing on this mechanism, "metabolically armored" INSR-overexpressing CAR-NK92 and primary CAR-T cells were engineered, which stabilized lipid rafts, preserved CAR expression, and improved antitumor activity in patient-derived organoids, precision-cut tumor slices, and xenografts. Collectively, these findings identify a stromal-mediated metabolic immune evasion pathway in gastrointestinal tumors, uncovering a potential strategy to potentiate CAR-engineered therapies.